Skip to main content

Arrowhead Inks Peptide Delivery Tech Deal with Shire

Premium

Arrowhead Research and Shire this week announced that they have struck an alliance to develop and commercialize drugs combining Arrowhead's targeted delivery peptides and Shire's therapeutic payloads.

Arrowhead acquired the peptide technology in April through its $2.1 million all-stock acquisition of Alvos Therapeutics (GSN 4/12/2012).

Under the deal, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type, permitting drug delivery.

Arrowhead stands to receive research funding, as well as development, regulatory, and commercialization milestones of up to $32.8 million for each drug candidate, plus royalties. Shire will have the option to exclusively license the candidates and would assume full responsibility for their development and marketing.

Additional terms were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.